Ariel Investments, an investment management company, released its “Ariel Appreciation Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund advanced +3.04% in the fourth quarter of 2025, outperforming the Russell Midcap Value Index’s +1.42% and the Russell Midcap Index’s +0.16% returns as U.S. equities posted a modest gain to cap a third consecutive year of double-digit returns despite earlier volatility, including a sharp spring sell-off, a prolonged government shutdown, and rising job cuts. For the trailing one-year period, the Fund gained +11.11%, modestly ahead of the Russell Midcap Value Index’s +11.05% and the Russell Midcap Index’s +10.60% return, while its 5- and 10-year average annual returns stood at +7.57% and +7.95%, respectively. Management credited resilient corporate earnings, easing inflation, and expectations for more accommodative monetary policy for restoring investor confidence. However, market gains remained concentrated in a narrow group of large-cap stocks, particularly those tied to artificial intelligence and cloud infrastructure. Looking ahead to 2026, the firm maintains a measured and cautious stance. It highlighted geopolitical risks, fiscal constraints, labor-market shifts, and elevated market concentration as key uncertainties. At the same time, management reaffirmed its disciplined, bottom-up approach centered on strong balance sheets, durable fundamentals, and long-term value creation. In addition, please check the Fund’s top five holdings to know its best picks in 2025.
In its fourth-quarter 2025 investor letter, Ariel Investments Appreciation Fund highlighted stocks like Charles River Laboratories International, Inc. (NYSE:CRL). Charles River Laboratories International, Inc. (NYSE:CRL) is a contract research company that provides drug discovery, development, and safety testing services to pharmaceutical and biotechnology firms worldwide. The one-month return of Charles River Laboratories International, Inc. (NYSE:CRL) was -7.30% while its shares traded between $91.86 and $228.88 over the last 52 weeks. On March 9, 2026, Charles River Laboratories International, Inc. (NYSE:CRL) stock closed at approximately $176.99 per share, with a market capitalization of about $8.284 billion.
Ariel Investments Appreciation Fund stated the following regarding Charles River Laboratories International, Inc. (NYSE:CRL) in its Q4 2025 investor letter:
“Charles River Laboratories (NYSE:CRL) also traded higher on solid quarterly results, reinforcing its position as a leader in outsourced drug development services. While biotech funding and large pharma budgets have moderated, outsourcing demand remains resilient and we believe CRL’s scale and capabilities position it well for recovery. Although near-term growth is pressured as big pharma prioritizes clinical programs over nonclinical work, we view these shifts as temporary since nonclinical testing is essential to replenishing pipelines. Longer term, CRL’s diversified portfolio and investments in high-growth areas like cell and gene therapy support durable growth and margin expansion. The company is streamlining operations, divesting non-core assets and maintaining leverage below 3x, while a new $1B share repurchase authorization underscores confidence in its outlook. Despite macro uncertainty and near-term headwinds, we believe CRL’s market opportunity is large, regulated and enduring; and its breadth and pricing power position it for renewed growth as demand normalizes.”
